ClinicalTrials.gg
CompletedNCT03749317Updated Oct 15, 2025

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

A Phase 2 interventional study of IVIEW-1201 and Placebo in Adenoviral Conjunctivitis, sponsored by IVIEW Therapeutics Inc.. Completed at 1 site in India. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by IVIEW Therapeutics Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
15 Years to 70 Years
Sex
All
01

Study summary

A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral Conjunctivitis

02

Conditions studied

  • Adenoviral Conjunctivitis

Browse trials for

Keywords

  • IVIEW-1201
  • Adenoviral Conjunctivitis
03

In context

Conjunctivitis

85 studies on the registry are indexed under Conjunctivitis; 5 are open to participants now.

This study's enrollment of 135 is below the median of 156 across 63 interventional studies indexed under Conjunctivitis.

Browse Conjunctivitis studies →

Lead sponsor

IVIEW Therapeutics Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. An understanding, ability, and willingness to fully comply with study procedures and restrictions.
  2. Ability to voluntarily provide written, signed, and dated to participate in the study.
  3. Subjects of age 15 and over at Visit 1.
  4. Have a positive AdenoPlus® test at Visit 1 in at least 1 eye.
  5. Have a clinical diagnosis of suspected adenoviral conjunctivitis in at least 1 eye (the same eye as the AdenoPlus positive eye) confirmed by the presence of the following minimal clinical signs and symptoms in that same eye:

    • Reported presence of signs and/or symptoms of adenoviral conjunctivitis for ≤ 3 days prior to Visit 1
    • Bulbar conjunctival injection: a grade of >=1 on 0-4 scale of Bulbar Conjunctival Injection Scale
    • Watery conjunctival discharge: a grade of >=1 (mild) on a 0-3 Watery Conjunctival Discharge Scale
  6. Be willing to discontinue contact lens wear for the duration of the study.
  7. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable requirements of the protocol or females of non-.

Exclusion criteria

Exclusion Criteria:

Subjects are excluded from the study if any of the following exclusion criteria are met.

  1. Current or recurrent disease that could affect the action, absorption, or disposition of the product, or clinical or laboratory assessments, per investigator's discretion.
  2. Current or relevant history of physical or psychiatric illness, any medical disorder that may make the subject unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
  3. Have known or suspected intolerance or to the investigational product, closely related compounds, or any of the stated ingredients.
  4. Prior enrollment in IVIEW-1201 clinical study.
  5. Subjects who are employees, or immediate family members of employees (who are directly related to study conduct), at the investigational site.
  6. Have a history of ocular surgical intervention within ≤ 6 months prior to Visit 1 or planned for the period of the study.
  7. Have a preplanned overnight hospitalization during the period of the study.
  8. Have presence of any intraocular, corneal, or conjunctival ocular inflammation (eg, uveitis, iritis, ulcerative keratitis, chronic blepharoconjunctivitis), other than adenoviral conjunctivitis.
  9. Have presence of corneal subepithelial infiltrates at Visit 1
  10. Have at enrollment or within ≤30 days of Visit 1, a clinical presentation more consistent with the diagnosis of ocular allergy, toxic conjunctivitis, or non-adenoviral ocular infection (eg, bacterial, fungal, acanthamoebae, other or parasitic).
  11. Age under 15.
  12. Prisoner.
  13. Presence of nasolacrimal duct obstruction at Visit 1 (Day 1).
  14. Presence of any significant ophthalmic condition (eg, Retinopathy of Prematurity, congenital cataract, congenital glaucoma) or other congenital disorder with ophthalmic involvement that could affect study variables.
  15. Have a history of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome; presence of corneal epithelial defect or any significant corneal opacity at Visit 1.
  16. Presence of significant, active condition in the posterior segment which requires invasive treatment (eg, intravitreal treatment with vascular endothelial growth factor (VEGF) inhibitors or ) and may progress during the study participation period.
  17. Have used any topical ocular or systemic anti-viral or antibiotics within \<= 7 days of enrollment.
  18. Have used any topical ocular NSAIDs within \<=1 day of enrollment.
  19. Have used any topical ophthalmic steroids in the last \<=14 days.
  20. Have used any systemic corticosteroid agents within \<=14 days of Day 1. Stable (initiated ≥30 days prior to enrollment) use of inhaled and nasal corticosteroids is allowed, given no anticipated change in dose for the duration of the study. Topical dermal steroids are allowed except in the peri-ocular area.
  21. Have used non-corticosteroid agents within \<=14 days of Day 1, oral or topical or both.
  22. Have used any topical ophthalmic products, including tear substitutes, and over-the-counter preparations such as lid scrubs, within 2 hours of Visit 1 and be unable to discontinue all topical ophthalmic products for the duration of the study. Use of hot or cold compresses is also not permitted during the study.
  23. Have any significant ocular disease (eg, Sjogren's syndrome) or any uncontrolled systemic disease or debilitating disease (eg, cardiovascular disease, hypertension, sexually transmitted diseases/infections, diabetes or cystic fibrosis), that may affect the study parameters, per Investigator's discretion.
  24. Any known history of immunodeficiency disorder or known active conditions predisposing to immunodeficiency, such as , or C, evidence of active hepatitis A (antihepatitis A virus immunoglobulin M), or organ or bone marrow transplantation.
  25. Within 30 days prior to the first dose of investigational product:

    1. Have used an investigational product or device, or
    2. Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this IVIEW-sponsored study.
  26. Pregnant women confirmed with dipstick urine pregnancy testing at Screening and at the final visit.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Treatment

    IVIEW-1201; four times per day (QID) for 7 days

    Drug: IVIEW-1201

  • Placebo comparator
    Placebo

    Placebo; four times per day (QID) for 7 days

    Drug: Placebo

Interventions

  • IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days

    Also known as: Treatment Arm

  • DrugPlacebo

    Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days

    Also known as: Placebo Treatment Arm

06

What researchers measure

Primary outcomes

  1. Clinical resolution by assessment of bulbar conjunctival injection and watery conjunctival discharge

    Proportion of subjects achieving clinical resolution (zero for conjunctival injection and discharge)

    Time frame: Day 6 +/- 1 Day

Secondary outcomes

  1. Viral Eradication

    Proportion of subjects with negative cell culture-immunofluorescence assay (CC-IFA)

    Time frame: Day 6 +/- 1 Day

07

Study locations

1 site
  • Disha Eye Hospital
    Kolkata, West Bengal 700120, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Apr 2024, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2018
First posted
Nov 21, 2018
StartActual
Feb 20, 2023
Primary completionActual
Apr 30, 2024
CompletionActual
Dec 31, 2024
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03749317
Lead sponsor
IVIEW Therapeutics Inc.
Responsible party
Sponsor
First posted
Nov 21, 2018
Start date
Feb 20, 2023
Primary completion
Apr 30, 2024
Completion
Dec 31, 2024
Last update
Oct 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IVIEW-1201

Start the discussion